LONDON, May 8 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP)(NASDAQ: SKYE) and Kos Pharmaceuticals, Inc. (Nasdaq: KOSP, "Kos") will host a joint teleconference later today to discuss the US development and marketing agreement for Flutiform(TM) announced this morning. SkyePharma's Chief Executive, Frank Condella, and Adrian Adams, President and Chief Executive of Kos, will present further information on the collaboration including information on each company's capabilities in the field of inhalation therapies. The conference call will be at 1330 BST / 0830 EDT today. The conference call will be available live via the Internet by accessing the website of either company at http://www.kospharm.com/ or http://www.skyepharma.com/ where the presentation slides will also be available. Please go to the respective website at least fifteen minutes prior to the call to register, download and install any necessary audio software. Those who cannot access the webcast can participate by telephone by calling +1-913-312-1295, confirmation code 6963745. A replay will also be available on both websites or by calling +1- 719-457-0820 and entering confirmation code 6963745 from 1130 EDT today until 2359 EDT on Friday, May 12, 2006. For further information please contact: SkyePharma PLC +44 207 491 1777 Frank Condella, Chief Executive Officer Peter Laing, Director of Corporate Communications +44 207 491 5124 Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000 Tim Anderson / Mark Court / Rebecca Skye Dietrich About SkyePharma SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now twelve approved products incorporating SkyePharma's technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit http://www.skyepharma.com/. Certain statements in this news release are forward-looking statements and are made in reliance on the safe harbour provisions of the U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will materialize. Because the expectations are subject to risks and uncertainties, actual results may vary significantly from those expressed or implied by the forward-looking statements based upon a number of factors, which are described in SkyePharma's 20-F and other documents on file with the SEC. Factors that could cause differences between actual results and those implied by the forward-looking statements contained in this news release include, without limitation, risks related to the development of new products, risks related to obtaining and maintaining regulatory approval for existing, new or expanded indications of existing and new products, risks related to SkyePharma's ability to manufacture products on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability to market products on a large scale to maintain or expand market share in the face of changes in customer requirements, competition and technological change, risks related to regulatory compliance, the risk of product liability claims, risks related to the ownership and use of intellectual property, and risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to revise or update any such forward-looking statement to reflect events or circumstances after the date of this release. DATASOURCE: SkyePharma PLC CONTACT: SkyePharma PLC: +44-207-491-1777, Frank Condella, Chief Executive Officer or Peter Laing, Director of Corporate Communications +44-207-491-5124; or Sandra Haughton, US Investor Relations +1-212-753-5780, or Tim Anderson, or Mark Court, or Rebecca Skye Dietrich, all of Buchanan Communications, +44-207-466-5000 Web site: http://www.skyepharma.com/ http://www.kospharm.com/

Copyright